Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting [Yahoo! Finance]
Cue Biopharma, Inc. (CUE)
US:NASDAQ Investor Relations:
cuebiopharma.gcs-web.com/news-releases
Company Research
Source: Yahoo! Finance
Median overall survival (mOS) of 20.8 months in second line (2L) and beyond HPV+ HNSCC patients treated with CUE-101 monotherapy compared with historical mOS of 7.5 and 8.4 months for third-party checkpoint inhibitor trials in 2L R/M HNSCC: CheckMate 141 and KEYNOTE-040 CUE-101 data will be presented in an oral presentation at ASCO today BOSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced updated data from its ongoing Phase 1 trial evaluating its lead oncology asset from the CUE-100 series of biologics, CUE-101. The data will be presented in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting today June 4, 2024, in Chicago, IL. Oral Presentation Details: Abstract Number Session Type and Title : Oral Abstract Session; Head and Neck Cancer Se
Show less
Read more
Impact Snapshot
Event Time:
CUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CUE alerts
High impacting Cue Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
CUE
News
- Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual MeetingGlobeNewswire
- Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024 [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024GlobeNewswire
- Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire
CUE
Earnings
- 5/9/24 - Beat
CUE
Sec Filings
- 6/7/24 - Form 4
- 6/7/24 - Form 3
- 6/7/24 - Form 4
- CUE's page on the SEC website